bremzalerbart (REGN5713) / Regeneron - LARVOL DELTA

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy (clinicaltrials.gov) - P3 | N=350 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Allergy • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology

Antibody Cocktail Targeting Bet v 1 Reduces Signs and Symptoms of Allergic Conjunctivitis in Birch Allergic Individuals Undergoing Conjunctival Allergen Challenge (AAAAI 2026) - "The treatment difference versus placebo for both ocular itch (3 min: -1.08, 5 min: -1.12, 7 min: -1.06; all p<0.0001) and conjunctival redness (7 min: -0.82; p<0.00001, 15 min: -0.78; p=0.0003, 20 min: -0.78; p=0.0003) were statistically significant at all time points assessed post-allergen challenge. Titrated SPT with birch demonstrated a Conclusions Single-dose REGN5713-5715 demonstrated reduction in allergic conjunctivitis signs and symptoms after birch allergen conjunctival allergen challenge in individuals with moderate-to-severe birch allergy, suggesting that allergen-specific IgG therapy may offer clinical benefit for birch allergy symptoms."

Clinical • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Otorhinolaryngology

Prediction of symptomatic relief in allergic individuals using a preclinical mouse model of allergic anaphylaxis (AAAAI 2026) - "Methods Baseline samples from cat-allergic or birch-allergic individuals enrolled in clinical studies for REGN1908-1909 cat allergen mAb cocktail or REGN5713-5714-5715 birch allergen mAb cocktail were utilized as the source of polyclonal IgE in the PCA model and PCA blockade was compared to clinical response. Logistic regression classification analyses further revealed modest-to-good accuracy in predicting clinical response across different blocking thresholds. Comparison Conclusions Data presented in the current study emphasizes ability of the in vivo PCA mouse model to predict clinical efficacy of allergen-specific mAbs."

Preclinical • Immunology

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy (clinicaltrials.gov) - P3 | N=350 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals

New P3 trial • Allergy • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology